8BD Stock Overview
Develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Boule Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.58 |
| 52 Week High | SEK 1.06 |
| 52 Week Low | SEK 0.55 |
| Beta | 0.48 |
| 11 Month Change | 1.41% |
| 3 Month Change | -16.52% |
| 1 Year Change | -32.47% |
| 33 Year Change | -87.74% |
| 5 Year Change | -90.71% |
| Change since IPO | -88.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8BD | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 3.6% | 2.4% | 0.8% |
| 1Y | -32.5% | -5.0% | 9.1% |
Return vs Industry: 8BD underperformed the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: 8BD underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 8BD volatility | |
|---|---|
| 8BD Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8BD has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 8BD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 200 | Torben Nielsen | www.boule.com |
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics companies.
Boule Diagnostics AB (publ) Fundamentals Summary
| 8BD fundamental statistics | |
|---|---|
| Market cap | €23.56m |
| Earnings (TTM) | -€18.42m |
| Revenue (TTM) | €48.82m |
0.5x
P/S Ratio-1.3x
P/E RatioIs 8BD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8BD income statement (TTM) | |
|---|---|
| Revenue | SEK 563.33m |
| Cost of Revenue | SEK 309.02m |
| Gross Profit | SEK 254.31m |
| Other Expenses | SEK 466.84m |
| Earnings | -SEK 212.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 11, 2025
| Earnings per share (EPS) | -5.47 |
| Gross Margin | 45.14% |
| Net Profit Margin | -37.73% |
| Debt/Equity Ratio | 64.3% |
How did 8BD perform over the long term?
See historical performance and comparison